secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2021-09-30T23:59:59+00:00
Accession:  0001193125-21-287430
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva's roluperidone bioequivalence study meets all PK objectives; pre-NDA meeting planned
--------------------------------------------------------------------------------

- Study showed bioequivalence in AUC_inf between Phase 2b, Phase 3, and planned commercial formulations.
- C_max reduced substantially in reformulated Phase 3 and commercial tablets vs Phase 2b formulation.
- Commercial formulation bioequivalent with or without food; 45 of 48 subjects completed study.
- Company to request pre-NDA meeting with FDA for roluperidone for negative symptoms of schizophrenia.
- No approved treatments in US for negative symptoms of schizophrenia; roluperidone is potential first-in-class.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312521287430/0001193125-21-287430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312521287430/d218690d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-287430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer